



ANTIMICROBIAL SUSCEPTIBILITY PROFILE (01/01/2023 to 12/31/2023)
MedStar Harbor Hospital

 Gram Negative Organisms	Percent Susceptible																			
	Number of Isolates	Amikacin***	Ampicillin	Ampicillin/subbactam	Aztreonam	Cefazolin (Systemic ¹)	Cefazolin (Urine ²)	Cefepime	Ceftazidime	Ceftioxone	Ciprofloxacin	ESBL (Negative)	Gentamicin***	Levofloxacin	Meropenem	Nitrofurantoin*	Piperacillin/azobactam	Tetracycline	Tobramycin***	Trimethoprim/Sulfa
<i>Acinetobacter baumannii</i> **	139	56	-	47	-	-	-	36	44	26	28	-	38	-	16	-	-	-	48	-
<i>Enterobacter cloacae</i>	35	100	-	0	69	-	-	77	66	63	86	-	100	-	100	45	69	82	94	94
<i>Escherichia coli</i>	575	100	47	54	87	44	84	87	86	86	66	87	93	-	100	98	96	72	91	70
<i>Klebsiella pneumoniae</i> ssp pneumoniae	138	99	0	68	84	54	89	84	83	83	82	84	93	-	99	44	88	74	91	86
<i>Proteus mirabilis</i>	64	98	77	88	97	0	92	97	97	92	70	-	92	-	-	0	100	0	92	84
<i>Pseudomonas aeruginosa</i>	97	99	-	-	81	-	-	93	84	-	86	-	-	-	91	-	85	0	98	-
<i>Serratia marcescens</i> **	108	100	5	1	97	-	-	95	95	79	94	-	100	-	95	-	96	-	82	85
<i>Stenotrophomonas maltophilia</i> **	98	-	-	-	-	-	-	-	26	-	-	-	-	76	-	-	-	-	-	99

 Gram Positive Organisms	Percent Susceptible																
	Number of Isolates	Ampicillin	Ceftriaxone (meningitis)	Ceftriaxone (non-meningitis)	Clindamycin	Daptomycin	Doxycycline	Erythromycin	Linezolid	Moxifloxacin	Nitrofurantoin*	Oxacillin	Penicillin (meningitis)	Penicillin (non-meningitis)	Tetracycline	Trimethoprim/Sulfa	Vancomycin
<i>Enterococcus faecalis</i>	146	100	-	-	-	100	-	-	100	-	100	-	-	-	29	-	95
<i>Enterococcus faecium</i>	34	-	-	-	-	98	-	-	100	-	-	-	-	-	-	-	41
Methicillin resistant <i>Staphylococcus aureus</i> (MRSA)***	39	-	-	-	65	98	97	19	100	-	-	0	-	-	90	62	100
Methicillin sensitive <i>Staphylococcus aureus</i> (MSSA)	50	-	-	-	0	0	0	53	99	-	-	100	-	-	93	94	100
<i>Staphylococcus coagulase-negative</i>	199	-	-	-	83	99	89	-	100	-	-	52	-	-	-	-	100
<i>Streptococcus pneumoniae</i> **	75	-	94	100	84	-	-	60	100	99	-	-	76	88	74	72	100

Percent Susceptible for each organism/antimicrobial combination was generated by including the first isolate of that organism encountered on a given patient
 (†) Drug not tested or drug not indicated
 (**) Tested on urine isolate only (***) Due to low incidence, organism incidence consists of totals from MFSMC, MGSB, MHH, and MUMH combined
 (****) MRSA rate of the institution was 44% (****) Based on CLSI M100-32nd Ed breakpoints
¹ Cefazolin (systemic), MIC ≤ 2 µg/mL, susceptible for infections other than uncomplicated UTIs
² Cefazolin (urine), MIC ≤ 16 µg/mL, susceptible